The global veterinary therapeutics market was valued at US$ 25,974.2 Mn in 2016 and is projected to increase significantly at a CAGR of 6.0% from 2017 to 2026. The therapeutics drugs segment in the global veterinary therapeutics market is estimated to account for major revenue share of 55.6% in 2017.
North America market is a dominant player in the global veterinary therapeutics market and accounts for largest market share in terms of revenue as compared to that of markets in other regions. This is attributed to well-developed animal healthcare industry, presence of leading animal vaccine manufacturers, and rise in number of disorders among companion animals, and livestock animals in countries in this region. Europe market accounts for the second largest revenue share contribution to the global veterinary therapeutics market followed by markets in Latin America, Asia Pacific and Middle East & Africa respectively.
Companies profiled in the report are Bayer AG, Boehringer Ingelheim GmbH, Ceva Inc, Dechra Pharmaceuticals PLC, Vetoquinol SA, Zoetis Inc., Virbac SA, Eli Lilly and Company, Merck Co. Inc.